Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS;Valutazione di una nuova associazione tra insulino-sensibilizzanti e acido α-lipoico in donne obese affette da PCOS

Minerva Ginecologica

Volumn 65, Issue 4, 2013, Pages 425-433

  Cappelli, V ^a   Di Sabatino, A ^a   Musacchio, M C ^a   De Leo, V ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Hyperandrogenism; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

INOSITOL; INSULIN SENSITIZING AGENT; METFORMIN; THIOCTIC ACID; ANTIOXIDANT; GLUCOSE BLOOD LEVEL; SEX HORMONE;

ARTICLE; BODY MASS; DIABETIC PATIENT; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; RESPIRATORY CHAIN; ADULT; ANALYSIS; BLOOD; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECTS; ELECTRON TRANSPORT; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIOXIDANTS; BLOOD GLUCOSE; BODY MASS INDEX; DRUG THERAPY, COMBINATION; ELECTRON TRANSPORT; FEMALE; GONADAL STEROID HORMONES; HOMEOSTASIS; HUMANS; INOSITOL; INSULIN RESISTANCE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; SEVERITY OF ILLNESS INDEX; THIOCTIC ACID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887427370     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale Hf. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8. (Pubitemid 32269197)
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9. (Pubitemid 38766360)
3. Goodarzi MO, Quinones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril 2005;84:766-9. (Pubitemid 41317746)
4. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
5. Rotterdam E. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
6. Kalro BN, Loucks TL, Berga SL. Neuromodulation in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:35-62. (Pubitemid 32242539)
7. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976;57:1320-9.
8. Berger MJ, Taymor ML, Patton WC. Gonadotropin levels and secretory patterns in patients with typical and atypical polycystic ovarian syndrome. N England J Med 1989;320:559-65.
9. Dahlgren E, Johansoon S, Lindstedt G, Kautsson F, Oden A, Jonson PO et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-13.
10. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weiner K et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Tromb Vasc Biol 1995;15:821-6.
11. Dunaif A. Insuline resistance and polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 1997;18:774-800. (Pubitemid 28009567)
12. Amowitz LL, Sobel BE. Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:439-58. (Pubitemid 29242723)
13. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006;29:278-85.
14. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356-9. (Pubitemid 13032489)
15. Ciaraldi TP, El-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SSC. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1982;75:577-83.
16. Marsden PJ, Murdoch A, Taylor R. Severe impairment of insulin action in adipocytes from amenorrhoeic subjects with polycystic ovary syndrome. Metabolism 1994;43:1536-42. (Pubitemid 24382705)
17. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SSC. Insulin, somatrotopic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common distinct features. J Clin Endocrinol Metab 1996;81:2854-9.
18. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392-5. (Pubitemid 27357930)
19. De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod 2006;21:2252-6. (Pubitemid 44530597)
20. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80. (Pubitemid 28287859)
21. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with PCOS. Fertil Steril 1999;72:282-5. (Pubitemid 29364624)
22. Lamer J. Multiple pathways in insulin signalling: fitting the covalent and allosteric puzzle pieces together. Endocr J 1994;2:167-71.
23. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics tolerability, and fructosamine-lowering effect of a novel, controlled release formulation of alpha-lipoic acid. Endocr Pract 2002;8:29-35.
24. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP activated protein kinase. Nat Med 2004;10:727-33. (Pubitemid 38937638)
25. Zacche MM, Caputo L, Filippis S, Zacchfe G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508-13.
26. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700-3. (Pubitemid 350261211)
27. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biolvol 2009;147:120-3.
28. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347-54. (Pubitemid 350200349)
29. De Leo V, La Marca A, Petraglia F. Insuline lowering agents in the management of PCOS. Endocr Rev 2003;24:633-67. (Pubitemid 37330585)
30. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin lowering agents. Expert Opin Pharmacother 2002;8:1177-89.
31. Franks S. Genetic and environmental origins of obesity relevant to reproduction. Rerod Biomed Online 2006;12:526-31. (Pubitemid 43674923)
32. AL-Nozha O, Habib F, Mojaddidi M, Fath El-Bab M. Body weight reduction and metformin: Roles in polycystic ovarysyndrome. Pathophysiology 2013;20:131-7.
33. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin lowering agents. Expert Opin Pharmacother 2002;8:1177-89.
34. De Leo V, La Marca A. Metformin and FSH for induction in women within polycistic ovary syndrome. Hum Rep 2002;17:2481-2. (Pubitemid 35021479)
35. Practice Committee of the American Society for Reproductive Medicine. Use of insulinsensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril 2008;90:69-S73.
36. Bozdag G, Yildiz BO. Interventions for the metabolic dysfunction in polycystic ovary syndrome. Steroids 2013 [In press].
37. Hosseini MA, Alleyassin A, Sarvi F, Safdarian L, Kokab A, Fanisalek M. Metformin treatment in different phenotypes of polycystic ovary syndrome. Arch Gynecol Obstet 2013 [In press].
38. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700-3. (Pubitemid 350261211)
39. Musacchio MC, Cappelli V, Di Sabatino A, Morgante G, De Leo V. Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women. Minerva Ginecol 2013;65:89-97.